MA45845A - Traitement d'association pour cancers hématologiques - Google Patents

Traitement d'association pour cancers hématologiques

Info

Publication number
MA45845A
MA45845A MA045845A MA45845A MA45845A MA 45845 A MA45845 A MA 45845A MA 045845 A MA045845 A MA 045845A MA 45845 A MA45845 A MA 45845A MA 45845 A MA45845 A MA 45845A
Authority
MA
Morocco
Prior art keywords
combination treatment
hematological cancers
hematological
cancers
treatment
Prior art date
Application number
MA045845A
Other languages
English (en)
Other versions
MA45845B1 (fr
Inventor
Fei Huang
Aleksandra Rizo
Joshua J Rusbuldt
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of MA45845A publication Critical patent/MA45845A/fr
Publication of MA45845B1 publication Critical patent/MA45845B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Glass Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA45845A 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique MA45845B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662370018P 2016-08-02 2016-08-02
EP16197293.0A EP3318276A1 (fr) 2016-11-04 2016-11-04 Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
US201662422738P 2016-11-16 2016-11-16
EP17748613.1A EP3493812B1 (fr) 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique
PCT/US2017/044348 WO2018026646A1 (fr) 2016-08-02 2017-07-28 Traitement d'association pour cancers hématologiques

Publications (2)

Publication Number Publication Date
MA45845A true MA45845A (fr) 2019-06-12
MA45845B1 MA45845B1 (fr) 2025-08-29

Family

ID=57226888

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45845A MA45845B1 (fr) 2016-08-02 2017-07-28 Combinaisons de l'imételstat et du vénétoclax destinées au traitement de la leucémie aigüe myéloblastique

Country Status (28)

Country Link
US (2) US11278561B2 (fr)
EP (3) EP3318276A1 (fr)
JP (3) JP7016856B2 (fr)
KR (3) KR102854375B1 (fr)
CN (2) CN116327954A (fr)
AU (2) AU2017305950B2 (fr)
CA (2) CA3217021A1 (fr)
CL (1) CL2019000228A1 (fr)
DK (1) DK3493812T3 (fr)
ES (1) ES2941462T3 (fr)
FI (1) FI3493812T3 (fr)
HR (1) HRP20230300T1 (fr)
HU (1) HUE061471T2 (fr)
IL (2) IL305332A (fr)
LT (1) LT3493812T (fr)
MA (1) MA45845B1 (fr)
MD (1) MD3493812T2 (fr)
MX (2) MX395085B (fr)
NZ (1) NZ750191A (fr)
PL (1) PL3493812T3 (fr)
PT (1) PT3493812T (fr)
RS (1) RS64074B1 (fr)
SG (1) SG11201900883UA (fr)
SI (1) SI3493812T1 (fr)
SM (1) SMT202300108T1 (fr)
UA (1) UA124935C2 (fr)
WO (1) WO2018026646A1 (fr)
ZA (1) ZA201900939B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (fr) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
KR20250151565A (ko) 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법
CA3087262A1 (fr) 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Composes benzamide
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
TWI865521B (zh) * 2019-04-29 2024-12-11 美商免疫遺傳股份有限公司 包含抗ｃｄ１２３免疫結合物之治療組合
KR20230041707A (ko) * 2020-07-17 2023-03-24 제론 코포레이션 피하 텔로머라제 억제제 조성물 및 이의 사용 방법
US20240108734A1 (en) * 2021-01-22 2024-04-04 The Regents Of The University Of California Methods for treating and ameliorating cancer
CN117897140A (zh) * 2021-07-16 2024-04-16 塞拉特药物股份有限公司 用于制备脂质体制剂的方法
WO2023141534A1 (fr) 2022-01-19 2023-07-27 Northwestern University Agents ciblant la transcriptase inverse de la télomérase (tert) pour traiter le cancer et sensibiliser des cellules cancéreuses à une thérapie génotoxique
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN118593709B (zh) * 2024-05-28 2025-05-23 湖南大学 Fasn抑制剂的新用途、化合物、化合物的新用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
DK1210357T3 (da) 1999-09-10 2008-07-21 Geron Corp Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
KR101298493B1 (ko) 2003-09-09 2013-08-21 제론 코포레이션 텔로머라제 억제를 위한 변형 올리고뉴클레오티드
US7998938B2 (en) 2005-04-15 2011-08-16 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (fr) 2005-04-15 2006-10-26 Geron Corporation Traitement de cancer par inhibition combinee des activites de la telomerase et de la tubuline
WO2006124904A2 (fr) 2005-05-16 2006-11-23 Geron Corporation Traitement du cancer par inhibition combinee de telomerase et d'activites hsp90
EP4474480A2 (fr) 2006-10-30 2024-12-11 Geron Corporation Inhibiteur de télomérase combiné et gemcitabine pour le traitement du cancer
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
ES2407957T3 (es) 2007-03-09 2013-06-17 Geron Corporation Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa
NO3029154T3 (fr) 2008-10-17 2018-03-03
WO2011017096A2 (fr) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Procédés de traitement de cancers hématologiques
PE20151604A1 (es) * 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
WO2014085632A1 (fr) 2012-11-30 2014-06-05 Geron Corporation Marqueurs de diagnostic pour le traitement de troubles de la prolifération cellulaire par des inhibiteurs de télomérase
HRP20240624T1 (hr) * 2012-12-07 2024-08-02 Geron Corporation Inhibitor telomeraze imetelstat za liječenje mijeloproliferativnih poremećaja i mijeloproliferativne neoplazme
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP2970225B1 (fr) * 2013-03-14 2018-08-15 Onyx Therapeutics, Inc. Dipeptides et tripeptides inhibiteurs d'epoxy cetone protease
WO2014160071A1 (fr) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Procédés et compositions pour le traitement de cancers dépendants à la glutamine
PT3065828T (pt) 2013-11-06 2019-04-01 Mayo Found Medical Education & Res Métodos e materiais para tratar malignidades hematológicas
US11034757B2 (en) * 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US9635050B2 (en) 2014-07-23 2017-04-25 Cisco Technology, Inc. Distributed supervised architecture for traffic segregation under attack
SG11201702316SA (en) 2014-09-24 2017-04-27 Cemm Forschungszentrum Für Molekulare Medizin Gmbh Monolayer of pbmcs or bone-marrow cells and uses thereof
EP3318276A1 (fr) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinaisons d'un inhibiteur de la télomérase et d'un inhibiteur du bcl-2 destinées au traitement des cancers hématologiques
KR20250151565A (ko) 2017-07-28 2025-10-21 제론 코포레이션 골수형성이상 증후군의 치료 방법

Also Published As

Publication number Publication date
CN109641002A (zh) 2019-04-16
IL264451B2 (en) 2024-01-01
US11278561B2 (en) 2022-03-22
IL305332A (en) 2023-10-01
JP7016856B2 (ja) 2022-02-07
MD3493812T2 (ro) 2023-05-31
MX2022010466A (es) 2022-09-19
SG11201900883UA (en) 2019-02-27
MX395085B (es) 2025-03-24
KR102854375B1 (ko) 2025-09-04
ES2941462T3 (es) 2023-05-23
MA45845B1 (fr) 2025-08-29
KR20230047206A (ko) 2023-04-06
CN116327954A (zh) 2023-06-27
LT3493812T (lt) 2023-04-11
DK3493812T3 (da) 2023-04-11
CA3032118A1 (fr) 2018-02-08
KR20250134002A (ko) 2025-09-09
PL3493812T3 (pl) 2023-05-08
US20220168333A1 (en) 2022-06-02
WO2018026646A1 (fr) 2018-02-08
KR20190049708A (ko) 2019-05-09
NZ750191A (en) 2023-03-31
HUE061471T2 (hu) 2023-07-28
CA3032118C (fr) 2023-12-12
CN109641002B (zh) 2022-10-18
HRP20230300T1 (hr) 2023-05-12
FI3493812T3 (fi) 2023-04-14
UA124935C2 (uk) 2021-12-15
BR112019002025A2 (pt) 2019-05-14
IL264451B1 (en) 2023-09-01
AU2017305950A1 (en) 2019-02-21
JP2024166290A (ja) 2024-11-28
AU2017305950B2 (en) 2023-06-22
EP3318276A1 (fr) 2018-05-09
CL2019000228A1 (es) 2019-05-17
JP2022145948A (ja) 2022-10-04
EP3493812B1 (fr) 2023-01-04
RS64074B1 (sr) 2023-04-28
ZA201900939B (en) 2023-04-26
AU2023229592A1 (en) 2023-10-05
EP4218768A1 (fr) 2023-08-02
JP2019523277A (ja) 2019-08-22
SI3493812T1 (sl) 2023-05-31
SMT202300108T1 (it) 2023-05-12
CA3217021A1 (fr) 2018-02-08
PT3493812T (pt) 2023-03-30
US20180036336A1 (en) 2018-02-08
MX2019001315A (es) 2019-07-01
EP3493812A1 (fr) 2019-06-12
IL264451A (en) 2019-02-28
KR102515378B1 (ko) 2023-03-29

Similar Documents

Publication Publication Date Title
FR25C1001I2 (fr) Compositions d'anticorps pour le traitement de tumeurs
MA45845A (fr) Traitement d'association pour cancers hématologiques
MA49144A (fr) Polythérapies pour le traitement du cancer
MA45192A (fr) Traitement d'association
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3431105A4 (fr) Composition médicinale pour le traitement du cancer
MA41449A (fr) Polythérapies pour le traitement de cancers
EP3452060A4 (fr) Polythérapie pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
EP3440493A4 (fr) Traitement d'échantillon pour microscopie
EP3400010A4 (fr) Combinaisons anti-her2 pour le traitement des tumeurs
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
EP3400011A4 (fr) Combinaisons anti-cd20 pour le traitement des tumeurs
EP3362066A4 (fr) Polythérapie pour le traitement de tumeurs malignes
EP3541417A4 (fr) Immunothérapies d'association pour le traitement du cancer
EP3630196A4 (fr) Polythérapies pour le traitement de cancers
EP3380200A4 (fr) Compositions pour le traitement des cheveux
EP3389645A4 (fr) Combinaisons pour le traitement du cancer
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3362065A4 (fr) Polythérapie pour le traitement de malignités
EP3490561A4 (fr) Combinaisons pour le traitement du cancer
EP3335041A4 (fr) Biomarqueurs pour le traitement de la pelade
EP3383407A4 (fr) Conjugués de cytarabine pour le traitement du cancer
EP3380063A4 (fr) Compositions pour le traitement des cheveux
EP3443962A4 (fr) Dérivé de quinoline pour le traitement du cancer de l'estomac